Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
Rangering i aksjer #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Aksjekurs
$0.01292666
Sist synkronisert: 2025-04-08
Markedsverdi
$157.54K
Endring (1 dag)
6.84%
Endring (1 år)
0.00%
Land
GB
Handel Synairgen plc (SNG)

Kategori

Inntekter for Synairgen plc (SNG)
Inntekter i Jun 2024 TTM: $-4.64M
Ifølge Synairgen plc sine nyeste økonomiske rapporter er selskapets nåværende resultat $-4.64M. I 2022 hadde selskapet et resultat på $-24.31M, en økning sammenlignet med resultatet i 2021, som var $-78.22M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Synairgen plc fra 2004 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-4.64M -62.26%
2023 $-12.29M -49.43%
2022 $-24.31M -68.92%
2021 $-78.22M 222.66%
2020 $-24.24M 281.43%
2019 $-6.36M 121,729.64%
2018 $-5.22K -336.99%
2017 $2.20K -100.05%
2016 $-4.20M 111,307.18%
2015 $-3.77K -315.15%
2014 $1.75K -100.05%
2013 $-3.75M -6.03%
2012 $-4.00M -32.03%
2011 $-5.88M 34.57%
2010 $-4.37M -6.90%
2009 $-4.69M -4.50%
2008 $-4.91M 29.79%
2007 $-3.78M 57.39%
2006 $-2.40M 119.97%
2005 $-1.09M 293.81%
2004 $-277.59K 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -113,800.85%
US
$1.95B -42,146.41%
NL
- -
CH
- -
KR
$3.01B -64,888.45%
BE